Phase 1/2 Open-label Study Of The Safety And Efficacy Of Pd 0332991 In Combination With Bortezomib And Dexamethasone In Patients With Refractory Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 25 Mar 2015
At a glance
- Drugs Palbociclib (Primary) ; Bortezomib; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 01 Mar 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 06 Sep 2012 Planned end date changed from 1 Jan 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.